Cryoballoon pulmonary vein isolation as first-line treatment of typical atrial flutter: long-term outcomes of the CRAFT trial.
Atrial fibrillation
Atrial flutter
Catheter ablation
Cryoballoon
Loop recorder
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
15
01
2024
accepted:
04
03
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
CRAFT was an international, multicentre, randomised controlled trial across 11 sites in the United UK and Switzerland. Given the evidence that pulmonary vein triggers may be responsible for atrial flutter (AFL) as well as atrial fibrillation (AF), we hypothesised that cryoballoon pulmonary vein isolation (PVI) would provide greater symptomatic arrhythmia reduction than cavotricuspid isthmus (CTI) ablation, whilst also reducing the subsequent burden of AF. Twelve-month outcomes were previously reported. In this study, we report the extended outcomes of the CRAFT study to 36 months. Patients with typical AFL and no evidence of AF were randomised 1:1 to cryoballoon PVI or radiofrequency CTI. All patients received an implantable loop recorder (ILR) for continuous cardiac rhythm monitoring. The primary outcome was time-to-symptomatic arrhythmia recurrence > 30 s. Secondary outcomes included time-to-first-AF episode ≥ 2 min. The composite safety outcome included death, stroke and procedural complications. A total of 113 patients were randomised to cryoballoon PVI (n = 54) or radiofrequency CTI ablation (n = 59). Ninety-one patients reconsented for extended follow-up beyond 12 months. There was no difference in the primary outcome between arms, with the primary outcome occurring in 12 PVI vs 11 CTI patients (HR 0.97; 95% CI 0.43-2.20; p = 0.994). AF ≥ 2 min was significantly less frequent in the PVI arm, affecting 26 PVI vs 36 CTI patients (HR 0.48; 95% CI 0.29-0.79; p = 0.004). The composite safety outcome occurred in 5 PVI and 6 CTI patients (p = 0.755). Cryoballoon PVI shows similar efficacy to radiofrequency CTI ablation in reducing symptomatic arrhythmia recurrence in patients presenting with isolated typical AFL but significantly reduces the occurrence of subsequent AF.
Sections du résumé
BACKGROUND
BACKGROUND
CRAFT was an international, multicentre, randomised controlled trial across 11 sites in the United UK and Switzerland. Given the evidence that pulmonary vein triggers may be responsible for atrial flutter (AFL) as well as atrial fibrillation (AF), we hypothesised that cryoballoon pulmonary vein isolation (PVI) would provide greater symptomatic arrhythmia reduction than cavotricuspid isthmus (CTI) ablation, whilst also reducing the subsequent burden of AF. Twelve-month outcomes were previously reported. In this study, we report the extended outcomes of the CRAFT study to 36 months.
METHODS
METHODS
Patients with typical AFL and no evidence of AF were randomised 1:1 to cryoballoon PVI or radiofrequency CTI. All patients received an implantable loop recorder (ILR) for continuous cardiac rhythm monitoring. The primary outcome was time-to-symptomatic arrhythmia recurrence > 30 s. Secondary outcomes included time-to-first-AF episode ≥ 2 min. The composite safety outcome included death, stroke and procedural complications.
RESULTS
RESULTS
A total of 113 patients were randomised to cryoballoon PVI (n = 54) or radiofrequency CTI ablation (n = 59). Ninety-one patients reconsented for extended follow-up beyond 12 months. There was no difference in the primary outcome between arms, with the primary outcome occurring in 12 PVI vs 11 CTI patients (HR 0.97; 95% CI 0.43-2.20; p = 0.994). AF ≥ 2 min was significantly less frequent in the PVI arm, affecting 26 PVI vs 36 CTI patients (HR 0.48; 95% CI 0.29-0.79; p = 0.004). The composite safety outcome occurred in 5 PVI and 6 CTI patients (p = 0.755).
CONCLUSION
CONCLUSIONS
Cryoballoon PVI shows similar efficacy to radiofrequency CTI ablation in reducing symptomatic arrhythmia recurrence in patients presenting with isolated typical AFL but significantly reduces the occurrence of subsequent AF.
Identifiants
pubmed: 38478165
doi: 10.1007/s10840-024-01786-y
pii: 10.1007/s10840-024-01786-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medtronic Europe
ID : AF-3908
Informations de copyright
© 2024. The Author(s).
Références
Ding WY, Williams E, Das M, Tovmassian L, Tayebjee M, Haywood G, et al. Cryoballoon pulmonary vein isolation as first line treatment for typical atrial flutter (CRAFT): study protocol for a randomised controlled trial. J Interv Card Electrophysiol. 2021;60(3):427–32.
doi: 10.1007/s10840-020-00746-6
pubmed: 32385774
Waldo A. Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin? Cardiovasc Res. 2002;54(2):217–29.
doi: 10.1016/S0008-6363(01)00549-1
pubmed: 12062328
Waldo AL. The interrelationship between atrial fibrillation and atrial flutter. Prog Cardiovasc Dis. 2005;48(1):41–56.
doi: 10.1016/j.pcad.2005.06.015
pubmed: 16194691
Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter. J Am Coll Cardiol. 2008;51(8):779–86.
doi: 10.1016/j.jacc.2007.08.066
pubmed: 18294560
Yugo D, Chen YY, Lin YJ, Chien KL, Chang SL, Lo LW, et al. Long-term mortality and cardiovascular outcomes in patients with atrial flutter after catheter ablation. Europace. 2022;24(6):970–8.
doi: 10.1093/europace/euab308
pubmed: 34939091
Ellis K, Wazni O, Marrouche N, Martin D, Gillinov M, McCarthy P, et al. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2007;18(8):799–802.
doi: 10.1111/j.1540-8167.2007.00885.x
pubmed: 17593230
Luria DM, Hodge DO, Monahan KH, Haroldson JM, Shen WK, Asirvatham SJ, et al. Effect of radiofrequency ablation of atrial flutter on the natural history of subsequent atrial arrhythmias. J Cardiovasc Electrophysiol. 2008;19(11):1145–50.
doi: 10.1111/j.1540-8167.2008.01206.x
pubmed: 18554204
Schneider R, Lauschke J, Tischer T, Schneider C, Voss W, Moehlenkamp F, et al. Pulmonary vein triggers play an important role in the initiation of atrial flutter: initial results from the prospective randomized atrial fibrillation ablation in atrial flutter (triple A) trial. Heart Rhythm. 2015;12(5):865–71.
doi: 10.1016/j.hrthm.2015.01.040
pubmed: 25638698
Providencia R, Defaye P, Lambiase PD, Pavin D, Cebron JP, Halimi F, et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? Europace. 2017 Jan;19(1):48–57.
Chun KRJ, Perrotta L, Bordignon S, Khalil J, Dugo D, Konstantinou A, et al. Complications in catheter ablation of atrial fibrillation in 3,000 consecutive procedures: balloon versus radiofrequency current ablation. JACC Clin Electrophysiol. 2017;3(2):154–61.
doi: 10.1016/j.jacep.2016.07.002
pubmed: 29759388
Gupta D, Ding WY, Calvert P, Williams E, Das M, Tovmassian L, et al. Cryoballoon pulmonary vein isolation as first-line treatment for typical atrial flutter. Heart. 2022 Nov 17;heartjnl-2022–321729.
Willems S, Khairy P, Andrade JG, Hoffmann BA, Levesque S, Verma A, et al. Redefining the blanking period after catheter ablation for paroxysmal atrial fibrillation: insights from the ADVICE (adenosine following pulmonary vein isolation to target dormant conduction elimination) trial. Circ Arrhythm Electrophysiol. 2016 Aug;9(8).
Boersma L, Andrade JG, Betts T, Duytschaever M, Pürerfellner H, Santoro F, et al. Progress in atrial fibrillation ablation during 25 years of Europace journal. Europace [Internet]. 2023 Aug 2;25(9). Available from: http://www.ncbi.nlm.nih.gov/pubmed/37622592
Navarrete A, Conte F, Moran M, Ali I, Milikan N. Ablation of atrial fibrillation at the time of cavotricuspid isthmus ablation in patients with atrial flutter without documented atrial fibrillation derives a better long-term benefit. J Cardiovasc Electrophysiol. 2011;22(1):34–8.
doi: 10.1111/j.1540-8167.2010.01845.x
pubmed: 20662976
Mohanty S, Natale A, Mohanty P, DI Biase L, Trivedi C, Santangeli P, et al. Pulmonary vein isolation to reduce future risk of atrial fibrillation in patients undergoing typical flutter ablation: results from a randomized pilot study (REDUCE AF). J Cardiovasc Electrophysiol. 2015 Aug;26(8):819–25
Steinberg JS, Romanov A, Musat D, Preminger M, Bayramova S, Artyomenko S, et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: The PReVENT AF study I. Heart Rhythm. 2014;11(9):1567–72.
doi: 10.1016/j.hrthm.2014.05.011
pubmed: 24832767
Romanov A, Pokushalov E, Bayramova S, Ponomarev D, Shabanov V, Losik D, et al. Prophylactic pulmonary vein isolation during isthmus ablation for atrial flutter: three-year outcomes of the PREVENT AF I study. J Cardiovasc Electrophysiol. 2018;29(6):872–8.
doi: 10.1111/jce.13485
pubmed: 29570894
Fu B, Ran B, Zhang H, Luo Y, Wang J. Prophylactic pulmonary vein isolation in typical atrial flutter patients without atrial fibrillation: a systematic review and meta-analysis of randomized trials. J Interv Card Electrophysiol. 2021;60(3):529–33.
doi: 10.1007/s10840-020-00772-4
pubmed: 32424664
Koerber SM, Turagam MK, Gautam S, Winterfield J, Wharton JM, Lakkireddy D, et al. Prophylactic pulmonary vein isolation during cavotricuspid isthmus ablation for atrial flutter: a meta-analysis. Pacing Clin Electrophysiol. 2019;42(5):493–8.
doi: 10.1111/pace.13637
pubmed: 30779174
Xie X, Liu X, Chen B, Wang Q. Prophylactic atrial fibrillation ablation in atrial flutter patients without atrial fibrillation: a meta-analysis with trial sequential analysis. Med Sci Monit Basic Res. 2018;30(24):96–102.
doi: 10.12659/MSMBR.910338
Pontoppidan J, Nielsen JC, Poulsen SH, Jensen HK, Walfridsson H, Pedersen AK, et al. Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: a randomised controlled trial. Heart. 2009;95(12):994–9.
doi: 10.1136/hrt.2008.153965
pubmed: 19261602
Mesquita J, Ferreira AM, Cavaco D, Carmo P, Madeira M, Freitas P, et al. Impact of prophylactic cavotricuspid isthmus ablation in atrial fibrillation recurrence after a first pulmonary vein isolation procedure. Int J Cardiol. 2018;259:82–7.
doi: 10.1016/j.ijcard.2018.01.025
pubmed: 29579616
Lee WC, Fang HY, Chen HC, Chen YL, Tsai TH, Pan KL, et al. Additional cavotricuspid isthmus block ablation may not improve the outcome of atrial fibrillation ablation. Pacing Clin Electrophysiol. 2019;42(11):1421–8.
doi: 10.1111/pace.13799
pubmed: 31482578
Romero J, Patel K, Briceno D, Lakkireddy D, Gabr M, Diaz JC, et al. Cavotricuspid isthmus line in patients undergoing catheter ablation of atrial fibrillation with or without history of typical atrial flutter: a meta-analysis. J Cardiovasc Electrophysiol. 2020;31(8):1987–95.
doi: 10.1111/jce.14614
pubmed: 32530541
Kim SH, Oh YS, Choi Y, Hwang Y, Kim JY, Kim TS, et al. Long-term efficacy of prophylactic cavotricuspid isthmus ablation during atrial fibrillation ablation in patients without typical atrial flutter: a prospective, multicentre, randomized trial. Korean Circ J. 2021;51(1):58–64.
doi: 10.4070/kcj.2020.0174
pubmed: 33150753
Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167–79.
doi: 10.1056/NEJMoa2303062
pubmed: 37622677